DDX3X is mutated to a lesser extent in DLBCL (3-5%), although recent analyses have shown a higher mutation rate (around 14%) in DLBCL tumors with altered MYC expression (108, 137–139). Here, DDX3X is linked to diffuse large B-cell lymphoma.